Robinson successfully defended his school from closure, fought for the unification of the teaching unions, mentored future trade union leaders and transformed teaching at the Marx Memorial Library, writes JOHN FOSTER
Public pharma v abusive prices: the case of the latest HIV-prevention drug
ALAN ROSSI SILVA argues that Gilead’s HIV prevention drug, while promising, highlights systemic failures in the pharmaceutical industry, showing the need to shift towards state-owned drug development and production
An electron micrograph of HIV-1 virus particles (colourized red) replicating from an HIV-infected H9 T-cell (blue)
A judge in a German court ruled that the ban activity imposed on renowned Dr Ghassan Abu-Sittah was unlawful, reports LEON WYSTRYCHOWSKI
At the very moment Britain faces poverty, housing and climate crises requiring radical solutions, the liberal press promotes ideologically narrow books while marginalising authors who offer the most accurate understanding of change, writes IAN SINCLAIR
From Gaza protest bans to proscribing Palestine Action, political elites are showing a crisis of confidence as they abandon Roy Jenkins’s apologetic approach for Suella Braverman’s aggressive ‘hate march’ rhetoric, writes PAUL DONOVAN
ANSELM ELDERGILL examines the legal case behind this weekend’s Tolpuddle Martyrs’ Festival and the lessons for today
Ben Chacko talks to RMT leader EDDIE DEMPSEY about how the key to fixing broken Britain lies in collective sectoral bargaining, restoring unions’ ability to take solidarity strike action and bringing about the much-vaunted ‘wave of insourcing’
The summer of 1950 saw Labour abandon further nationalisation while escalating Korean War spending from £2.3m to £4.7m, as the government meekly accepted capitalism’s licence and became Washington’s yes-man, writes JOHN ELLISON
LENACAPAVIR, an injectable antiretroviral drug developed by Gilead Sciences, recently made headlines after a Phase 3 clinical trial in South Africa and Uganda showed it to be 100 per cent effective in preventing HIV among women and adolescent girls.
Though hailed as a breakthrough in HIV prevention, lenacapavir serves as a stark reminder of the problems with the pricing of life-saving medicines.
While further data from this study and results from studies involving other populations are needed, lenacapavir could be considered the most durable HIV prevention method to show efficacy among women — a population for who biomedical HIV prevention evidence has been severely limited.
Similar stories
When privatisation is already so deeply embedded in the NHS, we can’t just blindly argue for ‘more funding’ to solve its problems, explain ESTHER GILES, NICO CSERGO, BRIAN GIBBONS and RATHI GUHADASAN
Despite miraculous trial results showing new treatment could halt transmission, corporate greed and patent laws condemn millions to preventable infection and death, write ROX MIDDLETON, LIAM SHAW and MIRIAM GAUNTLETT
Labour’s controversial plan to put the overweight and unemployed on the ‘skinny jab’ Mounjaro should set alarm bells ringing once we look into some of the research into the drug and the company set to supply it, warns CLAUDIA WEBBE
Keep Our NHS Public campaigner GREG DROPKIN dissects how Lord Darzi’s recommendations align with Starmer’s plans for NHS ‘reform,’ warning of creeping privatisation under the guise of modernisation